Mesoblast (MESO) has drawn renewed analyst interest ahead of pivotal clinical data readouts, with multiple firms upgrading their ratings and raising price targets. The biopharmaceutical company's advanced cell therapy pipeline is under increasing scrutiny as investors await results from ongoing trials.
- Mesoblast (MESO) is advancing multiple Phase 2 and Phase 3 trials with a focus on regenerative medicine applications.
- Three major brokerage firms have upgraded MESO to 'Buy' or 'Outperform' within the past month, citing potential for transformative data.
- The company’s cash runway extends through 2027, supported by a $45 million capital raise completed in Q3 2025.
- Analysts project a 60% to 80% probability of positive outcomes from the MB-102 knee osteoarthritis trial based on interim data trends.
- FDA Breakthrough Therapy designation for MB-102 remains intact, potentially accelerating regulatory review if trial results are favorable.
- Market capitalization of MESO stands at approximately $280 million as of December 15, 2025, reflecting growing investor interest.
Mesoblast (MESO) has emerged as a focal point for equity analysts following a wave of positive commentary centered on upcoming clinical trial data. The company's pipeline, particularly its allogeneic mesenchymal stem cell therapies for conditions like osteoarthritis and chronic graft-versus-host disease, is drawing attention due to near-term data milestones expected in early 2026. Analysts note that a Phase 2b trial for MesoBlast’s MB-102 candidate in knee osteoarthritis is progressing ahead of schedule, with top-line results anticipated by Q2 2026.